Condition: Advanced Cancer · Metastatic Cancer · Sponsor: Daiichi Sankyo
This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).
This description comes directly from the study's public registry record.
Daiichi Sankyo Contact for Clinical Trial Information · 908-992-6400 · CTRinfo@dsi.com
Always discuss trial participation with your own doctor first.
| Miami Cancer Institute | Miami, Florida, United States | Recruiting |
| Duke University - Trent Center | Durham, North Carolina, United States | Recruiting |
| Flinders Medical Center | Bedford Park, Australia | Active Not Recruiting |
| Monash Medical Center | Melbourne, Australia | Withdrawn |
| Grand Hôpital de Charleroi | Charleroi, Belgium | Recruiting |
| Instituto Aericas | Rio de Janeiro, Brazil | Not Yet Recruiting |
| A.C. Camargo Cancer Center | São Paulo, Brazil | Not Yet Recruiting |
| IBCC Nucleo de Pequisa e Ensino | São Paulo, Brazil | Not Yet Recruiting |
| Institut Gustave Roussy | Villejuif, France | Recruiting |
| Rabin Medical Center | Petah Tikva, Israel | Active Not Recruiting |
| Ospedale San Raffaele | Milan, Italy | Recruiting |
| Istituto Nazionale Tumori Fondazione G. Pascale | Naples, Italy | Withdrawn |
+ 16 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.